16-2029711-G-C
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_001130012.3(NHERF2):āc.343G>Cā(p.Ala115Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.0013 ( 0 hom., cov: 32)
Exomes š: 0.019 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
NHERF2
NM_001130012.3 missense
NM_001130012.3 missense
Scores
1
18
Clinical Significance
Conservation
PhyloP100: -1.75
Genes affected
NHERF2 (HGNC:11076): (NHERF family PDZ scaffold protein 2) This gene encodes a member of the NHERF family of PDZ scaffolding proteins. These proteins mediate many cellular processes by binding to and regulating the membrane expression and protein-protein interactions of membrane receptors and transport proteins. The encoded protein plays a role in intestinal sodium absorption by regulating the activity of the sodium/hydrogen exchanger 3, and may also regulate the cystic fibrosis transmembrane regulator (CFTR) ion channel. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Nov 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.08394036).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NHERF2 | NM_001130012.3 | c.343G>C | p.Ala115Pro | missense_variant | 2/7 | ENST00000424542.7 | NP_001123484.1 | |
NHERF2 | NM_004785.6 | c.343G>C | p.Ala115Pro | missense_variant | 2/7 | NP_004776.3 | ||
NHERF2 | XM_047434923.1 | c.343G>C | p.Ala115Pro | missense_variant | 2/7 | XP_047290879.1 | ||
NHERF2 | XM_047434924.1 | c.25G>C | p.Ala9Pro | missense_variant | 2/7 | XP_047290880.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NHERF2 | ENST00000424542.7 | c.343G>C | p.Ala115Pro | missense_variant | 2/7 | 1 | NM_001130012.3 | ENSP00000408005.2 |
Frequencies
GnomAD3 genomes AF: 0.00 AC: 191AN: 146062Hom.: 0 Cov.: 32 FAILED QC
GnomAD3 genomes
AF:
AC:
191
AN:
146062
Hom.:
Cov.:
32
FAILED QC
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 0.0186 AC: 11199AN: 602524Hom.: 0 Cov.: 31 AF XY: 0.0166 AC XY: 5203AN XY: 313026
GnomAD4 exome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
11199
AN:
602524
Hom.:
Cov.:
31
AF XY:
AC XY:
5203
AN XY:
313026
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Data not reliable, filtered out with message: AS_VQSR AF: 0.00129 AC: 189AN: 146182Hom.: 0 Cov.: 32 AF XY: 0.00146 AC XY: 104AN XY: 71084
GnomAD4 genome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
189
AN:
146182
Hom.:
Cov.:
32
AF XY:
AC XY:
104
AN XY:
71084
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 06, 2021 | The c.343G>C (p.A115P) alteration is located in exon 2 (coding exon 2) of the SLC9A3R2 gene. This alteration results from a G to C substitution at nucleotide position 343, causing the alanine (A) at amino acid position 115 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
.;T;.;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T;T;T
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
.;L;L;.
PrimateAI
Benign
T
PROVEAN
Benign
N;N;N;N
REVEL
Benign
Sift
Benign
T;T;T;D
Sift4G
Uncertain
D;T;T;T
Polyphen
0.0
.;B;.;.
Vest4
0.15, 0.20, 0.18
MutPred
0.37
.;Gain of relative solvent accessibility (P = 0.005);Gain of relative solvent accessibility (P = 0.005);.;
MVP
MPC
0.059
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at